Accendra Health, Inc. (ACH)
| Market Cap | 17.92M -95.8% |
| Revenue (ttm) | 2.65B -3.3% |
| Net Income | -302.14M |
| EPS | -3.95 |
| Shares Out | 76.90M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,821,911 |
| Open | 0.2300 |
| Previous Close | 0.2330 |
| Day's Range | 0.2227 - 0.2400 |
| 52-Week Range | 0.1910 - 5.3800 |
| Beta | 1.57 |
| Analysts | Hold |
| Price Target | 1.26 (+441.63%) |
| Earnings Date | Nov 5, 2026 |
About ACH
Accendra Health, Inc., together with its subsidiaries, operates as a healthcare solutions company in the United States. It offers a range of products and services for in-home care and delivery for diabetes treatment; home respiratory therapy, including home oxygen and non-invasive ventilation services; obstructive sleep apnea treatment, such as continuous positive airway pressure and bi-level positive airway pressure devices, and patient support services. The company also supplies other home medical equipment, patient care product lines includi... [Read more]
Financial Performance
In 2025, Accendra Health's revenue was $2.76 billion, an increase of 3.06% compared to the previous year's $2.68 billion. Losses were -$1.10 billion, 203.5% more than in 2024.
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for ACH stock is "Hold." The 12-month stock price target is $1.26, which is an increase of 441.63% from the latest price.
News
Accendra Health Proxy statement: Proxy filing
Accendra Health filed a proxy statement on October 29, 2026, providing details for shareholder voting and corporate governance matters.
Accendra Health Announces Third Quarter 2026 Earnings Release Date and Conference Call
RICHMOND, Va.--(BUSINESS WIRE)--Accendra Health, Inc. (NYSE: ACH) (the “Company”) plans to release financial results for the third quarter of 2026 on Thursday, November 5, 2026, after trading ends on ...
Accendra Health Proxy statement: Proxy filing
Accendra Health filed a proxy statement on October 19, 2026, providing details for shareholder voting and corporate governance matters.
Accendra Health Receives Continued Listing Standard Notice from NYSE; Intends to Cure Deficiency and Return to Compliance with NYSE Listing Standard
RICHMOND, Va.--(BUSINESS WIRE)--Accendra Health, Inc. (NYSE: ACH) (the Company) today announced that on October 6, 2026, it received a notice (the “Notice”) from the New York Stock Exchange (the “NYSE...
Accendra Health Names Kenneth Gardner-Smith as President and Chief Executive Officer to Lead the Company's Next Chapter of Growth
RICHMOND, Va.--(BUSINESS WIRE)--Accendra Health, Inc. (NYSE: ACH) (the “Company”) today named Kenneth Gardner-Smith as the Company's next President and Chief Executive Officer. Gardner-Smith, who has ...
Accendra Health updates capital allocation, CEO succession plans
Accendra Health (ACH) is providing an update on its capital allocation plans and the timeline for the replacement of its CEO. Given recent market conditions, the company has determined that…
Accendra Health Updates on Capital Allocation and CEO Succession Timing Plans
RICHMOND, Va.--(BUSINESS WIRE)--Accendra Health (the “Company”) is providing an update on its capital allocation plans and the timeline for the replacement of its chief executive officer. Given recent...
Accendra Health price target lowered to $1.50 from $4.50 at UBS
UBS lowered the firm’s price target on Accendra Health (ACH) to $1.50 from $4.50 and keeps a Neutral rating on the shares.
Accendra Health price target lowered to $1.30 from $2.70 at BofA
BofA analyst Allen Lutz lowered the firm’s price target on Accendra Health (ACH) to $1.30 from $2.70 and keeps an Underperform rating on the shares. The firm, which says Accendra…
Accendra Health downgraded to Neutral from Outperform at Baird
Baird downgraded Accendra Health (ACH) to Neutral from Outperform with a price target of $1.50, down from $6. The company’s earnings report “underwhelmed” driven by long-standing internal issues, the ...
Accendra Health downgraded to Neutral from Buy at Citi
Citi analyst Daniel Grosslight downgraded Accendra Health (ACH) to Neutral from Buy with a price target of $1.50, down from $4.50. The firm sees uncertainty around the company’s recovery after…
Accendra Health Earnings Call Transcript: Q2 2026
Second quarter results missed expectations due to revenue growth and collection rate challenges, but operational improvements, cost reductions, and new commercial agreements are expected to drive stronger performance in late 2026 and 2027. Debt was reduced by $400 million, and free cash flow is projected to be break-even for 2026.
Accendra Health Slides: Q2 2026
Accendra Health has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 10, 2026.
Accendra Health Earnings release: Q2 2026
Accendra Health released its Q2 2026 earnings on August 10, 2026, summarizing the period's financial results.
Accendra Health Quarterly report: Q2 2026
Accendra Health has published its Q2 2026 quarterly earnings report on August 10, 2026.
Accendra Health adopts Section 382 Rights Agreement
Accendra Health (ACH) announced that its Board of Directors adopted a Section 382 Rights Agreement designed to protect long-term shareholder value by facilitating the company’s ability to preserve its...
Accendra Health reports Q2 adjusted EPS (19c), consensus (9c)
Reports Q2 revenue $613.2M, consensus $627.31M. “Throughout Q2, we moved farther along toward the complete separation from Owens & Minor while also putting a large commercial payor exit behind us.
Accendra Health lowers FY26 revenue view to $2.45B-$2.55B from $2.55B-$2.65B
2026 revenue consensus $2.57B. Lowers 2026 adjusted EBITDA view to $300M-$320M from $335M-$355M.
Accendra Health Announces Adoption of Tax Asset Preservation Plan To Protect Long Term Shareholder Value
RICHMOND, Va.--(BUSINESS WIRE)--Accendra Health, Inc. (NYSE: ACH) (the Company) announced today that its Board of Directors adopted a Section 382 Rights Agreement (the “Tax Asset Preservation Plan”) d...
Accendra Health Reports Second Quarter 2026 Financial Results
RICHMOND, Va.--(BUSINESS WIRE)--Accendra Health, Inc. (NYSE: ACH) (the Company) today reported financial results for the second quarter ended June 30, 2026. Unless otherwise noted, the results herein ...
Accendra Health’s President and CEO Ed Pesicka intends to retire after 2026
Accendra Health (ACH) announced that President and CEO Edward Pesicka has informed the Board of Directors of his plan to retire by the end of 2026, after more than seven…
Accendra Health's Ed Pesicka Announces Intent to Retire; Board of Directors Has Begun Successor Search
RICHMOND, Va.--(BUSINESS WIRE)--Accendra Health, Inc. (NYSE: ACH) (the Company) today announced that President and Chief Executive Officer Edward A. Pesicka has informed the Board of Directors of his ...
Accendra Health Announces Second Quarter 2026 Earnings Release Date and Conference Call
RICHMOND, Va.--(BUSINESS WIRE)--Accendra Health, Inc. (NYSE: ACH) (the “Company”) plans to release financial results for the second quarter of 2026 on Monday, August 10, 2026, before trading begins on...
Accendra Health price target lowered to $4.50 from $5 at Citi
Citi lowered the firm’s price target on Accendra Health (ACH) to $4.50 from $5 and keeps a Buy rating on the shares.
Accendra Health files $200M mixed securities shelf
16:19 EDT Accendra Health (ACH) files $200M mixed securities shelf